Cell and gene therapies offer curative solutions to diseases but face high costs, scalability issues, and low affordability impacting patient access. Cell & gene therapy and vaccine manufacturers face the challenge of rapid and scalable responses to meet global health demands. Current viral vector production strategies fail to address a fundamental challenge – innate cellular defenses.
Virica is a cell enhancer company dedicated to improving manufacturing productivity and reducing costs, increasing access to cell and gene therapies by uniquely addressing the challenge of cellular defenses. Discover how Virica can deliver unparalleled success for you.
Small Molecule-Big Impact
Virica has developed a library of small molecule cell enhancers called Viral Sensitizers (VSE™), that temporarily reduce host cell defenses during production. This allows the virus to infect, transduce and replicate better. The outcome: higher yields, quality and scale-up success.
Productivity
Up to 7x Yield Increase*
Improved Quality
Improves critical quality attributes (CQAs)
Easily Integrates
Simple additive, platform agnostic, non detectable residuals
* yield enhancement depends on application
By combining our cloud-connected 250 mL bioreactors with Virica’s VSE enhancers and applying DoE optimization, we consistently achieved 2- to 5-fold increases in AAV titers. Virica’s deep technical expertise and commitment to open scientific dialogue made the integration of VSEs into Culture Biosciences’ bioreactors seamless. Together, Virica’s VSEs and our cutting-edge bioreactor platform enable us to accelerate client research and process development.
ReiThera has partnered with Virica to enhance its AAV production platform. Thanks to the support of Virica’s technical team—not only on the technical side but also through valuable scientific exchange—we successfully achieved our goal by combining the strengths of our two platforms: ReiThera’s proprietary cell line, ReiCell-AAV, and Virica’s VSEs. The use of their compounds led to a 3–4 fold increase in AAV productivity in our cells.
The NRC’s collaboration with Virica …brings us one step closer to accelerating the development of affordable and accessible … cell and gene therapies…
I’ve been researching the concept that innate cellular responses negatively impact vector production and felt it was imperative to test VSEs. I didn’t anticipate how significant their magnitude of enhancement would be both in terms of yield and full particle encapsidation.
Evaluated in Over 50 Applications
VSEs have been evaluated in 50+ applications across a wide range of cell lines and virus combinations for cell and gene therapy and vaccine production.
Virica’s High Throughput Virology (HTV™) platform ensures purpose-built and optimal VSE combinations for current and emergent applications.
